Under the partnership’s terms, Pfizer will invest in NovaMedica and the companies will construct a manufacturing facility in the Russian province of Kaluga, with construction set to begin mid-2017. The facility may be used to manufacture products for export markets, according to NovaMedica.
NovaMedica will manufacture the more than 30 sterile injectable products transferred from Pfizer at the Kaluga facility. The products include treatments for severe bacterial and fungal infections, cardiovascular disease, inflammatory diseases and cancer.
The partnership was announced in July 2016.
More articles on supply chain:
Ex-Turing CEO Martin Shkreli: US healthcare costs are up because of physicians, not drug prices
FDA approves first drug for rare spinal disease
FDA imposes clinical hold on Seattle Genetics’ cancer drug after 4 deaths
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
